dn-101
Prostate Cancer
Stanford UniversitySmall moleculePhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 59/ 100
Competitive context
427 Active assets in the Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Degarelix Bayer | Phase 4 | BBB |
AVOLVE Masonic Cancer Center, University of Minnesota | Phase 4 | BB |
Flotufolastat F-18 Washington University School of Medicine | Phase 4 | BB |
Estramustine The University of Texas Health Science Center, Houston | Phase 3 | BB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BB |
View all 50 →
Same molecule, other indications
dn-101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →